American Century Companies Inc. Invests $268,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

American Century Companies Inc. bought a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,787 shares of the company’s stock, valued at approximately $268,000.

Other hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock worth $16,539,000 after buying an additional 658,069 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth $239,000. Kennedy Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth $4,358,000. Allspring Global Investments Holdings LLC lifted its holdings in shares of 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 25.3% in the first quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock worth $74,551,000 after buying an additional 473,094 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 3.6 %

FDMT stock opened at $9.97 on Friday. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $36.25. The stock has a market capitalization of $515.48 million, a price-to-earnings ratio of -4.09 and a beta of 2.77. The firm’s fifty day simple moving average is $14.62 and its two-hundred day simple moving average is $21.45.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.90 million. As a group, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.75 EPS for the current year.

Analysts Set New Price Targets

FDMT has been the topic of several research analyst reports. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. BMO Capital Markets decreased their price target on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, July 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. Chardan Capital upped their price target on shares of 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,996 shares of the business’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $25.00, for a total transaction of $49,900.00. Following the transaction, the insider now owns 6,781 shares in the company, valued at $169,525. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO David Kirn sold 12,923 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total value of $290,638.27. Following the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Scott Bizily sold 1,996 shares of the company’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $25.00, for a total transaction of $49,900.00. Following the completion of the transaction, the insider now owns 6,781 shares in the company, valued at approximately $169,525. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,169 shares of company stock worth $396,146 over the last quarter. Insiders own 7.30% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.